Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus anlotinib followed by anlotinib maintenance in advanced soft tissue sarcoma after doxorubicin intolerance or failure
ChiCTR2300067650Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and anlotinib in soft tissue sarcoma (STS), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival rate at 24 weeks. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
eribulinanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300067650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067650.